LCT updates Diabecell trial
Wednesday, 11 February, 2009
Auckland’s Living Cell Technologies (LCT) has reported long-term follow-up results from seven patients implanted with its porcine islet product Diabecell in a Phase I/IIa trial in Russia.
Five patients who received double low-dose implants showed no safety concerns and maintained good blood glucose control. The other two patients on a single higher-dose implant also reported no safety concerns, the company said.
LCT’s medical director Professor Bob Elliott said none of the patients had problems with clinically relevant episodes of low blood glucose.
Common arthritis drug also lowers blood pressure
Scientists have known for a while that methotrexate helps with inflammation, but it may also help...
AI enables precise gene editing
A newly developed tool utilises AI to predict how cells repair their DNA after it is cut by gene...
Shingles vaccine may reduce risk of heart attack and stroke
Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...
